Bipartisan act unmutes US pharmacists on lower-cost drug options

11 October 2018
pharmacy_big

US President Donald Trump has signed legislation preventing so-called ‘gag clauses,’ used for years by pharmacy benefit managers to restrict access to cheaper off-plan options.

While said to be increasingly rare, a gag clause limits the information pharmacists can give to patients, preventing them from offering alternatives that would mean lower out-of-pocket costs.

Research indicates that certain Medicare patients could be paying over $100 million more for their prescriptions than is necessary.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical